BRAIN panels decide on next steps for the continuation of the industrialization strategy

BRAIN management team to be enlarged

03-Aug-2015 - Germany

BRAIN AG announces its next steps concerning the expansion of the company’s industrialization strategy, “BRAIN Agenda 2020”, which has been approved by the management board, supervisory board, and shareholders alike. The steady commitment to this strategy had already permitted a strongly growing group of companies operating in attractive markets to emerge over the past few years. The newly adopted expanded management structures will now form the basis for the company’s evolution in the industrial field.

In the enlarged BRAIN management team, co-founder Dr. Jürgen Eck has taken on the role of chairman and chief executive of BRAIN AG as of July 01, 2015. The long-standing CTO and deputy chairman thus succeeds Dr. Holger Zinke, who transferred to the supervisory board after his election by the general meeting of shareholders on July 08, 2015.

There, he has taken on the office of deputy chairman of the supervisory board following Michael Motschmann (chairman of MIG Verwaltungs AG). Mr. Motschmann, who had lent his support to the company since 2007 as a member of the supervisory board, deserves praise and thanks by the shareholders, the supervisory board and not least the management board of BRAIN for his tireless and committed efforts on the company’s supervisory body.

In addition to his role on the supervisory board, Dr. Zinke will reinforce his activities in the areas of economic and research policy, supporting the implementation of a bio-based economy (“bioeconomy”) in politics, the economy, and the capital market. Furthermore, he will head the newly created Industrial Advisory Panel, which consists of distinguished persons from the fields of economy, research, and politics and which will advise the company in matters of strategy.

In view of the growing operative areas within BRAIN AG, the longstanding heads of the “BioActives” and “Microbial Strain Development” technology units, Dr. Michael Krohn and Dr. Guido Meurer, as well as Dr. Martin Langer, who heads the "Corporate Development" corporate unit and who has been a part of the company for more than 20 years, have been appointed to the management team and granted full power of attorney. Together with the management board and the long-established head of Finance & Controlling, Rudolf Bröcker, they will, in future, be responsible for technology, strategy, business development, finances, and the operational business, in particular for the internationalization of the co-operation business and the extension of the product business.

In light of the development of BRAIN’s business operations, Thomas Kessler (former head of Global Platform Specialties with Merck KGaA) will join BRAIN’s Business Operations unit in order to strengthen it and manage its strategic orientation. The BRAIN Group’s management team was also enlarged by Frank Goebel (former Investment Director/Strategic Investment Group with the Expansion of BRAIN industrialization strategy Royal Bank of Scotland), who was tasked with the expansion of value chains by means of M&A activities.

https://www.bionity.com/en/news/153927/brain-panels-decide-on-next-steps-for-the-continuation-of-the-industrialization-strategy.html